Evaluating Cordyceps Militaris Capsules for COPD Lung Function Decline: A Study Protocol

A 48-week multi-center clinical trial protocol involving 160 patients aged 40-85 with mild-to-moderate stable COPD. The study, authored by Siqi Lin and published on figshare, is a randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of Cordyceps militaris capsules. The primary outcome is the change in post-bronchodilator FEV1 over a 24-week treatment period followed by a 24-week follow-up.

Use Cases

• Analyze clinical trial design and outcome measures for herbal interventions in COPD.
• Benchmark lung function metrics (FEV1, FVC, MMEF) against placebo-controlled study data.
• Study the relationship between patient-reported outcomes (CAT, CASA-Q, EQ-5D-5L) and physiological measures in COPD.
• Model time-to-event data based on the time to the first acute exacerbation secondary outcome.

Strengths

• Describes a specific, registered clinical trial (ChiCTR2400086743) with a clear protocol.
• Defines a precise sample size of 160 patients and a detailed 48-week study timeline.
• Lists multiple primary and secondary outcome measures, including lung function parameters and quality-of-life questionnaires.

Limitations

• The dataset is a study protocol PDF (946.3 KB); the actual trial results data are not included.
• Column-level documentation for any resultant data is absent; field semantics must be inferred from the protocol.
• The data file is small in scope, containing only the trial design document.

Provenance

Source

figshare

Collection Method

Designed as a clinical trial protocol.

Time Range

The trial involves a 48-week participant timeline (1-week run-in, 24-week treatment, 24-week follow-up).

Freshness

Last updated 2026-05-25 06:07:16; freshness should be verified.